Gyre Therapeutics (GYRE) Prepaid Assets (2010 - 2026)
Gyre Therapeutics (GYRE) reported Prepaid Assets of $3.8 million for Q1 2026, down 53.9% year-over-year from $8.2 million in Q1 2025, and up 33.07% on a QoQ basis from $2.8 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Prepaid Assets data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Prepaid Assets fell 53.9% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 53.9% YoY) and the FY2025 annual result came in at $2.8 million, up 96.87% from the prior year.
- Prepaid Assets climbed to $3.8 million in Q1 2026 per GYRE's latest filing, from $2.8 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $8.2 million in Q1 2025 and bottomed at $377000.0 in Q4 2022.
- The 5-year median for Prepaid Assets is $1.4 million (2024), against an average of $2.1 million.
- The widest annual swing landed in 2022, when Prepaid Assets slumped 89.03%; it then jumped 330.21% in 2025.
- Tracing GYRE's Prepaid Assets over 5 years: stood at $377000.0 in 2022, then jumped by 177.19% to $1.0 million in 2023, then surged by 37.42% to $1.4 million in 2024, then jumped by 96.87% to $2.8 million in 2025, then jumped by 33.07% to $3.8 million in 2026.
- Per Business Quant, the three latest GYRE Prepaid Assets figures stand at $3.8 million (Q1 2026), $2.8 million (Q4 2025), and $2.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.76 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | 2.87 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 8.16 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.17 Mn |
| Jun 30, 2023 | 697,000.00 |
| Mar 31, 2023 | 915,000.00 |
| Dec 31, 2022 | 377,000.00 |
| Sep 30, 2022 | 2.16 Mn |
| Jun 30, 2022 | 914,000.00 |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 8.32 Mn |
| Jun 30, 2021 | 8.33 Mn |
| Mar 31, 2021 | 8.51 Mn |
| Dec 31, 2020 | 6.84 Mn |
| Sep 30, 2020 | 3.54 Mn |
| Jun 30, 2020 | 1.99 Mn |
| Mar 31, 2020 | 2.38 Mn |
| Dec 31, 2019 | 4.20 Mn |
| Sep 30, 2019 | 4.19 Mn |
| Jun 30, 2019 | 4.07 Mn |
| Mar 31, 2019 | 3.68 Mn |
| Dec 31, 2018 | 3.81 Mn |
| Sep 30, 2018 | 3.54 Mn |
| Jun 30, 2018 | 2.66 Mn |
| Mar 31, 2018 | 1.74 Mn |
| Dec 31, 2017 | 1.33 Mn |
| Sep 30, 2017 | 849,000.00 |
| Jun 30, 2017 | 752,000.00 |
| Mar 31, 2017 | 1.04 Mn |
| Dec 31, 2016 | 958,000.00 |
| Sep 30, 2016 | 1.43 Mn |
| Jun 30, 2016 | 1.48 Mn |
| Mar 31, 2016 | 1.46 Mn |
| Dec 31, 2015 | 1.78 Mn |
| Sep 30, 2015 | 620,000.00 |
| Jun 30, 2015 | 379,000.00 |
| Mar 31, 2015 | 409,000.00 |
| Dec 31, 2014 | 103,000.00 |
| Sep 30, 2014 | 1.02 Mn |
| Jun 30, 2014 | 1.00 Mn |
| Mar 31, 2014 | 891,000.00 |
| Dec 31, 2013 | 999,000.00 |
| Sep 30, 2013 | 1.49 Mn |
| Jun 30, 2013 | 1.80 Mn |
| Mar 31, 2013 | 1.41 Mn |
| Dec 31, 2012 | 1.40 Mn |
| Sep 30, 2012 | 1.85 Mn |
| Jun 30, 2012 | 2.34 Mn |
| Mar 31, 2012 | 2.47 Mn |
| Dec 31, 2011 | 3.00 Mn |
| Sep 30, 2011 | 2.71 Mn |
| Jun 30, 2011 | 3.30 Mn |
| Dec 31, 2010 | 3.22 Mn |